Menu
Menu
Exciting news! We are thrilled to welcome Amrita Hospital to our network. Based in Faridabad, India, Amrita Hospital is recognized as one of the premier healthcare institutions. The hospital improves the well-being of the local community through initiatives aimed at providing outstanding and affordable medical care in the spirit of compassion to all.
The hospital will leverage the SOPHiA DDM™ platform to further its work with rare disorders and cancers, adding exome, solid tumor, and blood cancer applications. They will be able to conduct this testing in-house, allowing for faster turnaround times for our clinicians and researchers.
Dr. Moushumi Suryavanshi, Head of Molecular Biology at Amrita Hospital, said, “As we continue to innovate and search for the best tools to bring the highest level of care for our patients, it is imperative that we offer advanced Next Generation Sequencing testing for our practices.
By adding the capabilities of SOPHiA DDM™, we will be able to find answers to complex health problems faster by keeping our samples in-house. In addition, by joining the SOPHiA GENETICS network, we will also have the opportunity to learn from a global community and be able to contribute insights found from Indian genomic data to the larger global community.”
“It is our mission to democratize data-driven medicine and bring the power of world-class technology and global insights to healthcare institutions worldwide, so we can elevate the level care for all patients. We are honored to work with Amrita Hospital to advance the field of precision medicine for their patients,” added Ricardo Ramos Mendonca Filho, PhD., Managing Director, LAPAC, SOPHiA GENETICS.
Learn more about our SOPHiA DDM™ platform.
Join us at ESMO Asia 2025! Learn how we advance data-driven medicine, with our cloud-based SOPHiA DDM™ Platform by leveraging our unique AI-powered expertise and comprehensive product offering. Discover how we uncover insights from complex oncology data, driving faster discovery of new stratifying biomarkers, in addition to aiding in the commercialization of precision medicines.
We are excited to announce our presence at the World Companion Diagnostics & Liquid Biopsy Summit APAC. Meet our BioPharma team to learn more about our liquid biopsy portfolio and how it supports BioPharma companies to address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.
If you are around, don’t miss our Plenary talk, to discover how SOPHiA GENETICS is empowering Pharma companies to advance precision medicine with next-generation genomics solutions, enhancing worldwide patient access to innovative therapies
“Innovative Ways to Democratize Precision Medicine Testing”
Nicholas Tan, Managing Director APAC, SOPHiA GENETICS
We’re thrilled to be back at International Congress of Pathology and Laboratory Medicine (ICPALM 2025)
Join SOPHiA GENETICS at Booth S26 as we showcase our latest breakthroughs in data-driven medicine. Discover how our advanced solutions are transforming clinical insights across Liquid Biopsy, Solid Tumors, Hematologic Malignancies, and more.
We look forward to connecting with you in person in Malaysia!
Abu Dhabi, United Arab Emirates; June 3, 2025: M42, a global health leader powered by technology, continues to pioneer artificial intelligence (AI) and medical and clinical solutions as part of its mission to revolutionize health in the UAE and globally. In a major advancement for precision oncology, M42 announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS (Nasdaq: SOPH) to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of cancers.
As part of the collaboration, M42 will integrate SOPHiA GENETICS’ MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood draw. This approach does not replace but rather complements routine cancer screenings and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer profile. Over the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the UAE.
The new testing program will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the region. Validation studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 2025. Over time, the collaboration will serve as a foundation for broader expansion across the Middle East, excluding Saudi Arabia, delivering world-class precision oncology solutions to a wider population.
Albarah El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said: "At M42, we are committed to transforming care through innovation and collaboration. By partnering with AstraZeneca and SOPHiA GENETICS, we are bringing world-class liquid biopsy technologies to the UAE, empowering clinicians to deliver more precise and less invasive cancer care. This collaboration reflects our vision of democratizing health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalized care."
Sameh El Fangary, Cluster President GCC, AstraZeneca, shared," At AstraZeneca, we are leading the way in the application of precision medicine. Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimizing patient pathways from detection to therapy.”
Ross Muken, President of SOPHiA GENETICS, said: "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalize care, monitor disease in real-time, and ultimately improve outcomes for patients across the region."
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.
Join SOPHiA GENETICS at Pathology Update 2025 in Australia!
We are thrilled to announce our participation in the Pathology Update 2025, organized by the Royal College of Pathologists of Australasia (RCPA), for the very first time! This prestigious event will take place in Australia, showcasing the theme: 'Excellence in Diagnosis.'
Visit us at Booth #30 to discover how SOPHiA GENETICS is revolutionising the field of precision medicine. As clinicians and pathologists work tirelessly to achieve more accurate diagnoses and improve patient outcomes, we are here to support these efforts with our innovative, data-driven solutions.
Register to Pathology Update 2025 through here
We are thrilled to announce our participation in the ESMO Asia Congress 2024!
Join the SOPHiA GENETICS team at booth #E406 and explore how we are driving groundbreaking innovations in cancer research and treatment.
From our collaboration with Memorial Sloan Kettering cancer Center to decentralize MSK-ACCESS and MSK-IMPACT, to our launch of SOPHiA DDM™ Residual Acute Myeloid (RAM) Solution, we are committed to supporting clinical researchers with variant detection and analysis, biomarker discovery, and therapy selection.
We look forward to connecting with you at ESMO Asia 2024!
SOPHiA GENETICS™ is excited to be for the first time part of the BioJapan Congress. You will have the chance to chat with our team at booth to discuss our solutions and our universal SOPHiA DDM™ Platform.
Asia‘s Premier Hybrid Partnering Event
Oct 9 Wed - 11 Fri. 2024| PACIFICO Yokohama
The diagnostics company has implemented the SOPHiA DDM™ Platform to enhance its solid tumor testing
Boston, MA and Rolle, Switzerland, July 4, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA DDM™ Platform. The company will use SOPHiA GENETICS’ technology to enhance its solid tumor testing capabilities.
Dhiti Omics specializes in molecular diagnostic and genetic testing. By implementing SOPHiA DDM™ for the Agilent SureSelect Cancer CGP application, Dhiti Omics will improve its ability to provide researchers actionable information on mutations and biomarkers across hundreds of genes.
“Our team at Dhiti Omics is passionate about furthering the use of precision medicine and ensuring people in India and throughout the world have access to testing for better health outcomes,” said Sudha N. Rao, Ph.D., Founder and Director of Dhiti Omics Technologies. “Combining high-quality reagents, and powerful analytics into one unique workflow will help us maximize insights from comprehensive genomic profiling data. This will ensure we’re delivering the fastest and most accurate diagnostics to our customer base.”
SOPHiA DDM™ for SureSelect CGP application combines Agilent’s best-in-class genomic profiling assay kit with the SOPHiA DDM™ Platform. Launched in 2023, SureSelect Cancer CGP application offers comprehensive genomic profiling. With the SOPHiA DDM™ AI Platform, Dhiti Omics will have an integrated solution for rapid and accurate insights on the basis of the latest guidelines reflecting relevant biomarkers.
“Our Platform and applications are designed to enable companies like Dhiti Omics to more easily advance precision medicine,” said Ricardo Mendonca Filho, Ph.D., Managing Director, LAPAC, SOPHiA GENETICS. “By using SOPHiA DDM™, Dhiti Omics can ensure speed and accuracy of solid tumor testing to best support the Indian population.”
The combined efforts of Agilent and SOPHiA GENETICS make it possible for companies like Dhiti Omics to facilitate novel approaches to cancer research and diagnostics.
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Media Contact:
Kelly Katapodis
media@sophiagenetics.com
SOPHiA GENETICS technology helps advance cancer research across India
SOPHiA GENETICS and Karkinos Healthcare join forces to propel cutting-edge genomic solutions for breakthroughs in personalized cancer care in India
Boston, MA and Rolle, Switzerland, January 15, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Karkinos Healthcare, a purpose-driven cancer care technology network based in India, will partner with SOPHiA GENETICS and adopt the SOPHiA DDM™ Platform to advance cancer testing and research for blood cancers and solid tumors to underserved areas in low and middle-income countries.
Karkinos Healthcare is a purpose-driven, technology-led oncology platform, focused on early detection, advanced diagnostics, and treatment delivery of common cancers, using its Distributed Cancer Care Network across India. Karkinos Healthcare provides end-to-end solutions for oncology ecosystem, including disease screening, diagnosis, surgery, chemotherapy, radiotherapy and comprehensive patient navigation through the care continuum, in addition to operating advanced research and development laboratories. The company is on a mission to create ‘Community as a Cancer Centre’ with an endeavour to serve one million patients annually by addressing the accessibility and affordability gaps in cancer care through a digitally curated hub and spoke and further spoke model, and not restrict cancer care to comprehensive centres alone.
“It is our continued goal to improve health outcomes for patients globally by expanding access to precision oncology and equipping local health institutions with the tools and technology needed to practice data-driven medicine,” said Dr. Jurgi Camblong, CEO and Co-founder, SOPHiA GENETICS. “By aligning with Karkinos, who share the mutual goal, we can help increase the use of best-in-class cancer testing for rural and underserved communities around the world.”
On this strategic partnership, Dr. R Venkataramanan, Founder and CEO, Karkinos Healthcare said, “Through collaborative research initiatives, Karkinos Healthcare aims to address the comprehensive genomic landscape identification for Indian population, with a focus on precision medicine. This alliance will have the potential to generate evidence and world-class research for faster and accurate diagnosis and better control and management of cancers, particularly for the underprivileged population of our country.”
The SOPHiA DDM™ Platform is designed to compute a wide array of genomic variants and continually hone machine learning algorithms to detect rare and challenging cases. Karkinos Healthcare will use SOPHiA GENETICS’ technology to expand its offerings, advance research and streamline workflow for a variety of blood cancers, including Myeloid cancer and Lymphoma. In addition, the company will analyse solid tumours for a variety of cancer types including ovarian, prostate, breast, pancreas, lung, colorectal, skin, and brain cancers.
The SOPHiA DDM™ Platform offers tailored NGS-based workflows to streamline processes – from sample to report – to accelerate analysis. By using the SOPHiA DDM™ Platform, researchers from Karkinos Healthcare will quickly obtain high-quality and reproducible data that will ultimately accelerate clinical research studies and advance the use of precision medicine.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on X, LinkedIn,Facebook, and Instagram. Where others see data, we see answers.
Product Disclaimer
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS: Forward-Looking Statement
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
About Karkinos Healthcare
Karkinos Healthcare is a purpose driven technology-led oncology health care platform for early detection and diagnosis of common cancers. The organisation espouses use of a distributed cancer care network, while working with a network of healthcare institutions and domain experts within the ecosystem, with an aim to provide comprehensive cancer care closer to individuals’ homes.
Tata Group, Reliance Industries, Mayo Clinic, and Rakuten Medical Inc. are among the World’s leading organizations that have invested in Karkinos Healthcare. The company has also partnered with Tata Memorial Hospital, Guys and St Thomas NHS Foundation Trust (UK), and has inked several research collaborations with leading academic institutions in the United States to stay on the cutting edge of oncology treatment and care.
To learn more, visit https://www.karkinos.in/about-us/
Media Contacts:
Kelly Katapodis
media@sophiagenetics.com
Team Corporate Communications
media@karkinos.in
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.